BPC-157: gut-healing research peptide (Body Protection Compound 157)
A synthetic peptide originally isolated from human stomach juice that speeds tissue healing and protects the gut lining in animal studies; reached Phase 2 clinical trials for inflammatory bowel disease but is not an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a partial sequence of a larger protein first isolated from human gastric juice. Predrag Sikiric and colleagues at the University of Zagreb, Croatia identified this fragment in the early 1990s and found it retained the parent protein's cytoprotective activity. The peptide is unusually stable compared to most short peptides — a polyproline motif at positions 3–5 of the sequence (Pro-Pro-Pro) confers resistance to enzymatic degradation, which contributes to its oral bioavailability relative to most short peptides. BPC-157 is not FDA-approved, not EMA-authorized, and has no completed controlled human efficacy trial for any indication.
Also known as: Body Protection Compound-157, Bepecin, PL-14736, PL-10, Pentadecapeptide.
History
BPC-157 research began in the early 1990s at the University of Zagreb under Predrag Sikiric and colleagues, who isolated and characterized a cytoprotective protein from human gastric juice. The 15-residue fragment was synthesized and found to retain — and in some models exceed — the cytoprotective properties of the full-length parent protein (Sikiric and colleagues 2020, Gut and Liver). Over the following three decades the Zagreb group and collaborators published extensively on BPC-157 across multiple organ systems.
A Phase II clinical trial for inflammatory bowel disease was sponsored by Croatian pharmaceutical company Pliva under the development code PL-14736. Partial results were published and the trial established early tolerability signals. The program was discontinued after Teva acquired Pliva and did not advance to Phase III.
The peptide entered the sports and wellness markets in the 2010s primarily through compounding pharmacies and gray-market research-chemical suppliers, well before any regulatory body evaluated it for approved therapeutic use.
What it does
In animal models, BPC-157 accelerates healing of tendons, ligaments, and the gut mucosa, and shows cytoprotective effects across multiple organ systems. Gwyer and colleagues (2019, Cell and Tissue Research) reviewed the evidence for accelerated musculoskeletal soft tissue healing, covering tendon and ligament repair across rodent models. Gut protection — particularly against NSAID-induced damage — is among the most consistently demonstrated effects in preclinical work. Additional animal model evidence covers muscle repair, bone healing, neuroprotection, cardiovascular protection, and modulation of the nitric oxide system (Sikiric and colleagues 2020, Gut and Liver).
Human efficacy is unestablished. No controlled human efficacy trial has been completed for any indication.
Evidence
- Human: Very limited. A small open-label IV safety study (Lee & Burgess 2025, n=2 healthy adults, 10 mg then 20 mg IV infusion) reported no adverse events on cardiac, hepatic, renal, thyroid, or metabolic markers, and plasma returned to baseline within 24 hours — a safety signal only, no efficacy endpoints. An uncontrolled interstitial cystitis pilot (Lee, Walker, Ayadi 2024, n=12 women) reported symptom resolution in all participants after a single intravesical injection of 10 mg; the absence of a control group limits interpretation. The Pliva Phase II IBD trial (PL-14736) established early clinical tolerability; it was discontinued without Phase III. No published controlled human efficacy RCT exists for any indication.
- Animal: Extensive. Tendon and ligament healing, gut mucosal protection, NSAID-induced damage reversal, muscle repair, bone healing, neuroprotection, cardiovascular and vascular models have all been characterized in rodent studies. The large majority of publications originate from the Sikiric laboratory or direct collaborators; independent replication exists but is limited, and this single-laboratory concentration is a recognized caveat for interpreting preclinical effect sizes.
- In vitro: FAK-paxillin pathway activation in tendon fibroblast scratch assays; enhanced growth hormone receptor expression in tendon fibroblasts; VEGF and eNOS upregulation in cell and tissue models.
A 2026 systematic review of BPC-157 in orthopaedic sports medicine confirmed the musculoskeletal healing signal across preclinical studies while flagging the complete absence of controlled human data.
Known effects
- Tendon and ligament healing — Preclinical (rodent models); consistent signal across multiple studies and research sites; independent replication limited
- Gut mucosal protection and NSAID-damage reversal — Preclinical (rodent models); most extensively studied indication; clinical trial abandoned before Phase III
- Muscle injury recovery — Preclinical; animal models demonstrate accelerated skeletal muscle healing
- Angiogenesis promotion — Preclinical and in vitro; VEGF, EGF, FGF, HGF upregulation documented
- Nitric oxide system modulation — Preclinical and in vitro; vasomotor tone regulation characterized in animal models
- Human efficacy (any indication) — Not established; no controlled human trial completed
Safety signals
Animal data: No lethal dose was established in rodent studies at doses far exceeding reported therapeutic ranges. Preclinical safety assessment (Xu and colleagues 2020) found no evidence of hormonal suppression, HPA axis effects, or organ growth in animal models.
Human pilot data: The Lee & Burgess 2025 IV safety pilot (n=2) reported no adverse events on any assessed biomarker. Community self-report aggregations in the available literature describe injection-site soreness as the most frequently cited adverse event; mild nausea (oral route) and transient dizziness are also reported.
Theoretical concern — angiogenic activity: BPC-157 upregulates VEGF and other angiogenic growth factors. Source notes this raises a theoretical concern for tumor promotion in individuals with active malignancy or recent cancer history. This concern has not been observed in animal studies but has not been formally addressed by long-duration rodent carcinogenicity studies or human pharmacovigilance.
Quality and purity concern: BPC-157 is primarily sold as a gray-market research compound. University laboratory testing of gray-market vials has documented bacterial endotoxin contamination, incorrect molecular weight, and in some cases incorrect peptide identity — considered the primary practical safety concern for community users, distinct from the molecule's intrinsic risk profile.
Regulatory status
- US (FDA): Not approved for any indication. Removed from the FDA 503A Category 2 compounding list (April 22, 2026; nominations withdrawn). FDA stated intent to consult the Pharmacy Compounding Advisory Committee (PCAC) on July 23, 2026 regarding BPC-157 acetate and free-base forms; outcome pending.
- EU (EMA): Not authorized.
- UK (MHRA): Not licensed.
- Australia (TGA): Schedule 4 prescription-only substance; enforcement action has been taken against unapproved sale.
- WADA: Prohibited under S0 (non-approved substances for human therapeutic use, 2022 update); multiple athlete sanctions documented under S0.
Mechanism
BPC-157 does not act through a single receptor. Animal models and cell assays have characterized several interconnected pathways:
- VEGF, EGF, FGF, HGF upregulation — promotes angiogenesis and tissue granulation at injury sites in rodent models
- eNOS / nitric oxide system modulation — vasodilation and blood flow regulation; modulatory effects on vasomotor tone and the nitric oxide system have been characterized in animal studies
- FAK-paxillin pathway — promotes fibroblast migration to damage sites; characterized in tendon fibroblast scratch assays; growth hormone receptor expression enhancement in tendon fibroblasts has been documented
- Dopaminergic system (D1/D2) — attenuation of haloperidol-induced catalepsy in rat models suggests D2 receptor pathway involvement; BPC-157 also interacts with dopaminergic and GABAergic systems
- Serotonergic effects — described in rat gastric ulcer models
Sikiric and colleagues have described these convergent effects under the framework of "cytoprotection" and "adaptive cytoprotection" — a broad protective program across organ systems (Sikiric and colleagues 2020, Gut and Liver). Which of these pathways are primary drivers of observed healing versus secondary correlates remains unresolved.
The raw sequence (GEPPPGKPADDAGLV, 15 aa, MW 1419) is a free-acid linear peptide with no fatty-acid conjugation, disulfide bonds, or acetyl/amide end-caps. The polyproline stretch at positions 3–5 is the structural feature most associated with its proteolytic stability.
Open questions
- Long-term human safety — no study extends beyond short observational windows; chronic-use data at any scale is absent
- Human pharmacokinetics — absorption, distribution, metabolism, and excretion characterized only in rodents; route-comparative bioavailability (oral vs. subcutaneous vs. IV) is unresolved in humans
- Carcinogenicity — VEGF upregulation raises a theoretical tumor-promotion concern not yet addressed by long-duration carcinogenicity studies
- Independent replication — the large majority of preclinical publications originate from Sikiric's group; independent effect-size confirmation from other laboratories is a recognized gap
- Mechanism specificity — primary vs. secondary pathway among VEGF/angiogenesis, NO system, FAK-paxillin, dopaminergic, and serotonergic effects is unresolved
- Commercial development barrier — patent expiration on the core molecule is cited as a structural barrier to industry-funded Phase III trials; this is the economic explanation offered in the available literature for the absence of Phase III data after three decades of preclinical work
Myths and misconceptions
- "BPC-157 is FDA-approved for injury recovery" — It is not approved for any indication. It has not completed Phase II or III human efficacy trials. Its historical availability in the US via compounding pharmacies has narrowed following the FDA's 2026 decision to remove it from the 503A Category 2 list.
- "The animal data is so strong it proves it works in humans" — The preclinical literature is broad and mechanistically consistent, but animal effect sizes do not reliably predict human outcomes. Human controlled efficacy data is absent after more than three decades of research. The honest framing: strong preclinical rationale, unproven in humans.
- "BPC-157 is a steroid or works like one" — BPC-157 is a short peptide fragment derived from a gastric juice protein. It has no structural or pharmacological relationship to anabolic-androgenic steroids, does not bind androgen receptors, and does not suppress endogenous testosterone.
- "Oral BPC-157 is as effective as injected BPC-157 for muscle and joint injuries" — Systemic bioavailability of oral BPC-157 in humans has not been rigorously characterized. The preclinical musculoskeletal models used injection near affected tissue; oral administration has the strongest mechanistic rationale for gut-focused applications where local mucosal exposure is the goal.
Related peptides
- TB-500 (Thymosin Beta-4) — a thymic peptide also widely discussed for soft tissue repair; different mechanism (actin dynamics, cell migration) but studied in overlapping musculoskeletal indications in the preclinical literature.
- GHK-Cu — a copper-binding tripeptide with documented collagen-remodeling and wound-healing effects; sometimes combined with BPC-157 in compounded formulations.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Can we stop the gut damage caused by modern cancer drugs without also stopping them from fighting the tumor?
Some of the most effective cancer drugs cause severe colon inflammation, and the standard fix (steroids, biologics) can blunt the very immune response killing the tumor. If this holds, BPC-157 could calm the gut lining through a completely separate route, so patients could stay on their cancer treatment longer rather than stopping it to manage side effects.
Is there a way to take NSAIDs (like ibuprofen or naproxen) long-term without damaging the small intestine?
Most people who take anti-inflammatory painkillers daily, whether for arthritis or chronic pain, develop silent damage in their small intestine that current stomach-protecting drugs simply do not reach. If this holds, an oral peptide could fill that gap and give chronic pain patients a safer long-term option where nothing approved currently exists.
Is there a small tail on this peptide that acts like an anchor, and without it does the whole thing stop working?
If the last four building blocks of BPC-157 act as a docking hook that positions the molecule where it needs to be, that would explain why it works at extraordinarily tiny doses, and it would give chemists a clear rule for building smaller, more potent versions rather than working blind.
If BPC-157 boosts blood vessel repair, does that mean it could accidentally help tumors grow?
A key worry about using BPC-157 in cancer patients is that anything that encourages blood vessel growth might feed a tumor. If this holds, the opposite could be true: tumor blood vessels lack the very biological machinery BPC-157 relies on, so the protection would land in healthy tissue only, potentially clearing the way for its use in cancer patients who need gut or injury support.
Does one specific building block in this peptide control blood vessel effects separately from its tissue-healing effects?
BPC-157 appears to do several things at once, which makes it hard to use precisely. If a single building block (position 7 in the chain) is responsible for the vascular effects, swapping it out could produce a version that heals tissue without touching blood pressure regulation, making it much safer for long-term use.
What if you connected two ends of this peptide to form a loop, would it work better and last longer in the body?
BPC-157 has never had proper drug optimization work done on it, partly because researchers do not know exactly where it binds. A ring-shaped version could be more potent in lab tests, which would give scientists the first concrete evidence of how structure relates to effect, and could reopen a development path that stalled years ago.
▸full evidence table1 metrics
| metric | value | tool |
|---|---|---|
| ranking score | 0.7380773425102234 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | none_monomer |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-23 |
▸citationbibtex
@peptide{pep00001,
sequence = {GEPPPGKPADDAGLV},
target = {tissue-repair},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}